Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | SPR | P35270 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989480 | 0.84 | CYP2C9 (0.52) | CYP2C9CYP2C19MAPK14HTR2BSPR | |
| SCHEMBL6990102 | 0.80 | PROKR1 (0.50) | SPRMGLL | |
| SCHEMBL4143776 | 0.75 | CYP2C9 (0.54) | CYP2C9CYP2C19MAPK14HTR2BSPR | |
| SCHEMBL3696474 | 0.75 | CYP2C9 (0.56) | CYP2C9CYP2C19MAPK14HTR2BMGLL | |
| SCHEMBL6987252 | 0.74 | HSD11B1 (0.50) | SPRKMT2A | |
| SCHEMBL17730097 | 0.73 | HTT (0.69) | CYP2C9CYP2C19MAPK14HTR2BSPR | |
| SCHEMBL6990139 | 0.72 | SCD5 (0.53) | — | |
| SCHEMBL12936207 | 0.72 | CCR2 (0.61) | CYP2C9CYP2C19MAPK14HTR2BSPR | |
| SCHEMBL3455111 | 0.71 | SLC6A2 (0.64) | CYP2C9CYP2C19MAPK14HTR2BMGLL | |
| SCHEMBL30442105 | 0.71 | CYP2C9 (0.73) | CYP2C9CYP2C19MAPK14HTR2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | CYP2C9 3038/4885CYP2C19 3227/4885MAPK14 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.